Carmignani G, Maffezzini M, Monti Bragadin C, Samer L, Gusmitta A, Cantoni L, Caglio G
Istituto di Clinica Urologica, Università di Trieste.
Arch Ital Urol Nefrol Androl. 1992 Jun;64(2):145-53.
Eighteen patients of either sex (14 M; 4 F), ranging in age from 23 to 79 years, with clinical diagnosis of complicated cystitis due to Rufloxacin sensitive pathogens, were enrolled. Rufloxacin was administered orally at the dosage of 400 mg/die the first day; 200 mg/die the following 6 days or more. The mean duration of treatment was 7.25 +/- 0.78 days. No concomitant antimicrobial therapy was administered during the study. At the end of therapy 5/14 evaluable patients recovered, 9/14 evaluable patients improve; 4 patients were considered by Investigator as "not evaluable". Causative pathogens were isolated in all patients and eradicated in 18 out of 18 bacteriologically evaluable patients (eradication rate = 100%). Neither reinfections nor superinfections occurred. No clinical adverse event related to study medication was reported. The results indicate that Rufloxacin at the oral dose of 200 mg/die is well tolerated and effective in the treatment of complicated cystitis.
纳入了18例年龄在23至79岁之间的患者，男女不限（男性14例；女性4例），临床诊断为由对芦氟沙星敏感的病原体引起的复杂性膀胱炎。芦氟沙星首日口服剂量为400mg/日，随后6天及更长时间为200mg/日。平均治疗时长为7.25±0.78天。研究期间未给予联合抗菌治疗。治疗结束时，14例可评估患者中5例康复，9例改善；4例被研究者视为“不可评估”。所有患者均分离出致病病原体，18例细菌学可评估患者中18例病原体被清除（清除率 = 100%）。未发生再感染或二重感染。未报告与研究用药相关的临床不良事件。结果表明，口服剂量为200mg/日的芦氟沙星耐受性良好，对复杂性膀胱炎治疗有效。
